USD 15.08
| ticker | 1 day return % | 1 week return % | 1 month return % | 3 months return % | 6 months return % | 1 year return % | 3 years return % | 5 years return % | 10 years return % | maximum return % |
|---|---|---|---|---|---|---|---|---|---|---|
| TXG | -0.1 | -8.0 | 12.4 | -2.3 | -8.9 | -64.1 | -83.7 | -82.8 | -71.4 | -71.4 |
| S&P 500 | 1.0 | 3.7 | 2.1 | 2.3 | 8.2 | 25.4 | 31.0 | 80.6 | 196.5 | 33856.2 |
Our interactive price chart includes various drawing tools to help you analyze the product more effectively. Below is a quick guide on how to use these tools: Full Guideline
Feel free to experiment with these tools to enhance your technical analysis. Remember, any drawings you make are temporary and will be lost upon refreshing the page unless saved as an image using the 'Camera' icon.
Get instant AI-powered professional insights on prices:
💡Generate AI Technical Analysis ReportA Multi-Interval Candlestick Chart displays the price movements of an asset over different time intervals. Each candlestick represents the open, high, low, and close prices for a specific interval. The chart can be used to identify trends and patterns in price movements.
| Attribute | Value |
|---|---|
| symbol | TXG |
| name | 10x Genomics, Inc. |
| price | 15.08 |
| changes percentage | -0.0663 |
| change | -0.01 |
| day low | 14.9 |
| day high | 15.5 |
| year high | 51.22 |
| year low | 12.95 |
| market cap | 1825501151 |
| price avg 50 | 15.0955 |
| price avg 200 | 20.498075 |
| exchange | NASDAQ |
| volume | 1280083 |
| avg volume | 1923714 |
| open | 15.46 |
| previous close | 15.09 |
| eps | -1.52 |
| pe | -9.92 |
| earnings announcement | 2025-02-11T10:59:00.000+0000 |
| shares outstanding | 121054453 |
| timestamp | 2025-01-17 21:00:00 |
We derive the score of a company's financial statements by evaluating the weighted average sentiment across key within the statements. The cumulative score, normalized to a sum of 1, serves as a metric for assessing the company's performance during the specified period. A higher score indicates stronger performance. However, it's crucial to note that while this score provides valuable insights, it is just one of many factors to consider when making informed investment decisions. A holistic evaluation, considering various aspects of the company's financial health and market conditions, is essential for a well-rounded investment strategy.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001770787 | |||
| revenue | 618727000 | 516409000 | 19.81 |
| gross profit | 409313000 | 396023000 | 3.36 |
| gross profit ratio | 0.66 | 0.77 | -13.74 |
| research and development expenses | 270332000 | 265667000 | 1.76 |
| operating expenses | 674949000 | 563967000 | 19.68 |
| interest income | 16906000 | 6647000 | 154.34 |
| interest expense | 33000 | 476000 | -93.07 |
| ebitda | -205111000 | -128489000 | -59.63 |
| ebitdaratio | -0.33 | -0.31 | -6.00 |
| operating income | -194949000 | -167944000 | -16.08 |
| operating income ratio | -0.32 | -0.33 | 3.12 |
| net income | -255099000 | -166000000 | -53.67 |
| net income ratio | -0.41 | -0.32 | -28.26 |
| eps | -2.18 | -1.46 | -49.32 |
Revenue Growth: revenue increased to 619 million in 2023 from 516 million in 2022 representing a change of 19.81%. This indicates a sales growth, which is a positive sign for the company.
Gross Profit: Gross Profit increased to 409 million in 2023 from 396 million in 2022 representing a change of 3.36%. This indicates a sales profitability growth, which is a positive sign for the company.
Research and Development (R&D) Expenses: R&D Expenses increased to 270 million in 2023 from 266 million in 2022 representing a change of 1.76%. This shows that the company continues to invest in innovation and product development, which is crucial for long-term growth.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) increased to -205 million in 2023 from -128 million in 2022 representing a change of -59.63%. The increase in EBITDA indicates improved operational efficiency and profitability.
Operating Income: Operating income increased to -195 million in 2023 from -168 million in 2022 representing a change of -16.08%. The increase in operating income indicates better operational performance and increased profitability.
Net Income: Net income increased to -255 million in 2023 from -166 million in 2022 representing a change of -53.67%. The increase in net income shows improved profitability and indicates that the company is generating more profit for each dollar of revenue.
Operating Expenses: Operating Expenses increased to 675 million in 2023 from 564 million in 2022 representing a change of 19.68%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.
Earnings per Share (EPS): EPS increased to -2.18 in 2023 from -2.18 in 2022 representing a change of -49.32%. This indicates that the company's earnings are decreasing and it is becoming less profitable on a per-share basis.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001770787 | |||
| revenue | 151654000 | 153104000 | -0.95 |
| gross profit | 106393000 | 106896000 | -0.47 |
| gross profit ratio | 0.7 | 0.7 | 0.48 |
| research and development expenses | 66174000 | 62918000 | 5.17 |
| operating expenses | 147878000 | 148633000 | -0.51 |
| interest income | 4971000 | 4715000 | 5.43 |
| interest expense | 2000 | 1000 | 100.00 |
| ebitda | -23686000 | -26178000 | 9.52 |
| ebitdaratio | -0.16 | -0.2 | 22.46 |
| operating income | -41485000 | -41737000 | 0.60 |
| operating income ratio | -0.27 | -0.27 | -0.35 |
| net income | -35753000 | -37897000 | 5.66 |
| net income ratio | -0.24 | -0.25 | 4.76 |
| eps | -0.3 | -0.32 | 6.25 |
Revenue Growth: revenue decreased to 152 million in 2024Q3 from 153 million in 2024Q2 representing a change of -0.95%. This indicates a sales shrinking, which is a negative sign for the company.
Gross Profit: Gross Profit decreased to 106 million in 2024Q3 from 107 million in 2024Q2 representing a change of -0.47%. This indicates a sales profitability decline, which is a negative sign for the company.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) decreased to -24 million in 2024Q3 from -26 million in 2024Q2 representing a change of 9.52%. The decrease in EBITDA indicates declined operational efficiency and profitability.
Operating Income: Operating income decreased to -41 million in 2024Q3 from -42 million in 2024Q2 representing a change of 0.6%. The decrease in operating income indicates worse operational performance and decreased profitability.
Net Income: Net income decreased to -36 million in 2024Q3 from -38 million in 2024Q2 representing a change of 5.66%. The decrease in net income shows worsen profitability and indicates that the company is generating less profit for each dollar of revenue.
Research and Development (R&D) Expenses: R&D Expenses increased to 66 million in 2024Q3 from 63 million in 2024Q2 representing a change of 5.17%. This shows that the company continues to invest in innovation and product development, which is crucial for long-term growth.
Operating Expenses: Operating Expenses decreased to 148 million in 2024Q3 from 149 million in 2024Q2 representing a change of -0.51%. The decrease in operating expenses can be attributed to various factors such as improved profitability, cost optimization and financial stability, lower operating expenses can be positive indicators.
Earnings per Share (EPS): EPS increased to -0.3 in 2024Q3 from -0.3 in 2024Q2 representing a change of 6.25%. This indicates that the company's earnings are increasing and it is becoming more profitable on a per-share basis.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001770787 | |||
| total assets | 965143000 | 1028980000 | -6.20 |
| total liabilities | 224100000 | 223237000 | 0.39 |
| total equity | 741043000 | 805743000 | -8.03 |
| cash and cash equivalents | 359284000 | 219746000 | 63.50 |
| short term investments | 29411000 | 210238000 | -86.01 |
| long term investments | 0 | 4974000 | -100.00 |
| total current assets | 596022000 | 635035000 | -6.14 |
| total non current assets | 369121000 | 393945000 | -6.30 |
| total current liabilities | 127162000 | 130957000 | -2.90 |
| total non current liabilities | 96938000 | 92280000 | 5.05 |
| common stock | 2000 | 2000 | 0.00 |
| retained earnings | -1284420000 | -1029321000 | -24.78 |
| total debt | 95370000 | 95176000 | 0.20 |
Total Assets: Total Assets decreased to 965 million in 2023 from 1,029 million in 2022 representing a change of -6.2%. Suggesting a decrease in asset holdings.
Total Liabilities: Total Liabilities increased to 224 million in 2023 from 223 million in 2022 representing a change of 0.39%. This indicates an increase in overall liabilities.
Total Equity: Total Equity decreased to 741 million in 2023 from 806 million in 2022 representing a change of -8.03%. This indicates a decrease in shareholders' equity.
Short Term Investments: Short Term Investments decreased to 29 million in 2023 from 210 million in 2022 representing a change of -86.01%. This indicates a decrease in short-term investment holdings.
Total Current Assets: Total Current Assets decreased to 596 million in 2023 from 635 million in 2022 representing a change of -6.14%. This indicates a worsen liquidity position.
Retained Earnings: Retained Earnings decreased to -1,284 million in 2023 from -1,029 million in 2022 representing a change of -24.78%. This indicates an accumulated losses.
Total Debt: Total Debt increased to 95 million in 2023 from 95 million in 2022 representing a change of 0.2%. This indicates an increase in overall debt burden.
Cash And Cash Equivalents: Cash And Cash Equivalents increased to 359 million in 2023 from 220 million in 2022 representing a change of 63.5%. This indicates an increase in available liquid assets.
Total Current Liabilities: Total Current Liabilities decreased to 127 million in 2023 from 131 million in 2022 representing a change of -2.9%. This indicates a lower short-term debt burden.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001770787 | |||
| total assets | 937794000 | 929668000 | 0.87 |
| total liabilities | 214990000 | 205610000 | 4.56 |
| total equity | 722804000 | 724058000 | -0.17 |
| cash and cash equivalents | 398159000 | 379824000 | 4.83 |
| short term investments | 0 | 269000 | -100.00 |
| long term investments | 0 | 0 | NaN |
| total current assets | 593893000 | 579155000 | 2.54 |
| total non current assets | 343901000 | 350513000 | -1.89 |
| total current liabilities | 121235000 | 111019000 | 9.20 |
| total non current liabilities | 93755000 | 94591000 | -0.88 |
| common stock | 2000 | 2000 | 0.00 |
| retained earnings | -1418019000 | -1382266000 | -2.59 |
| total debt | 85876000 | 89482000 | -4.03 |
Total Assets: Total Assets increased to 938 million in 2024Q3 from 930 million in 2024Q2 representing a change of 0.87%. Suggesting a growth in asset holdings.
Cash And Cash Equivalents: Cash And Cash Equivalents increased to 398 million in 2024Q3 from 380 million in 2024Q2 representing a change of 4.83%. This indicates an increase in available liquid assets.
Total Current Assets: Total Current Assets increased to 594 million in 2024Q3 from 579 million in 2024Q2 representing a change of 2.54%. This indicates a better liquidity position.
Total Debt: Total Debt decreased to 86 million in 2024Q3 from 89 million in 2024Q2 representing a change of -4.03%. This indicates a reduction in overall debt burden.
Total Liabilities: Total Liabilities increased to 215 million in 2024Q3 from 206 million in 2024Q2 representing a change of 4.56%. This indicates an increase in overall liabilities.
Total Equity: Total Equity decreased to 723 million in 2024Q3 from 724 million in 2024Q2 representing a change of -0.17%. This indicates a decrease in shareholders' equity.
Short Term Investments: Short Term Investments decreased to 0 million in 2024Q3 from 0 million in 2024Q2 representing a change of -100.0%. This indicates a decrease in short-term investment holdings.
Total Current Liabilities: Total Current Liabilities increased to 121 million in 2024Q3 from 111 million in 2024Q2 representing a change of 9.2%. This indicates a higher short-term debt burden.
Retained Earnings: Retained Earnings decreased to -1,418 million in 2024Q3 from -1,382 million in 2024Q2 representing a change of -2.59%. This indicates an accumulated losses.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001770787 | |||
| net change in cash | 131931000 | -368720000 | 135.78 |
| operating cash flow | -15197000 | -33606000 | 54.78 |
| free cash flow | -64721000 | -165267000 | 60.84 |
| capital expenditure | -49524000 | -131661000 | 62.39 |
| depreciation and amortization | 43619000 | 33006000 | 32.15 |
| deferred income tax | 0 | 0 | NaN |
| stock based compensation | 166950000 | 136848000 | 22.00 |
| accounts payables | -6017000 | 5858000 | -202.71 |
| inventory | 7871000 | -21192000 | 137.14 |
| acquisitions net | 0 | -4000000 | 100.00 |
| investments in property plant and equipment | -48601000 | -131661000 | 63.09 |
| net cash used for investing activites | 133491999 | -350887000 | 138.04 |
| debt repayment | 0 | 0 | NaN |
| common stock issued | 19483000 | 21226000 | -8.21 |
| common stock repurchased | 0 | 0 | NaN |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | 13669000 | 15817000 | -13.58 |
| cash at end of period | 359284000 | 227353000 | 58.03 |
| accounts receivables | -10613000 | -18948000 | 43.99 |
| cash at beginning of period | 227353000 | 596073000 | -61.86 |
Net Change in Cash: Net Change in Cash increased to 132 million in 2023 from -369 million in 2022 representing a change of 135.78%. Indicating an increased ability to generate cash from the company's operations or its cash flow position.
Operating Cash Flow: Operating Cash Flow increased to -15 million in 2023 from -34 million in 2022 representing a change of 54.78%. This indicates that the company generated more cash from its core business operations.
Free Cash Flow: Free Cash Flow increased to -65 million in 2023 from -165 million in 2022 representing a change of 60.84%. This indicates an increase in cash generated after accounting for capital expenditures.
Capital Expenditure: Capital Expenditure increased to -50 million in 2023 from -132 million in 2022 representing a change of 62.39%. This indicates an increase in the cash outflow required for acquiring or improving long-term assets.
Stock-Based Compensation: Stock-Based Compensation increased to 167 million in 2023 from 137 million in 2022 representing a change of 22.0%. This indicates increased expenses, which is generally considered a negative sign from a financial perspective.
Accounts Payables: The absolute value of Accounts Payables increased to 6 million in 2023 from 6 million in 2022 representing a change of -202.71%. This indicates that the company has increased its outstanding obligations to its suppliers.
Accounts Receivables: Accounts Receivables increased to -11 in 2023 from -19 million in 2022 representing a change of 43.99%. This suggests that the company is less capable of collecting payments from its customers.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001770787 | |||
| operating cash flow | 21641000 | 7496000 | 188.70 |
| free cash flow | 17752000 | 3618000 | 390.66 |
| capital expenditure | -3889000 | -3878000 | -0.28 |
| depreciation and amortization | 10750000 | 10900000 | -1.38 |
| deferred income tax | 0 | 0 | NaN |
| stock based compensation | 33588000 | 38492000 | -12.74 |
| accounts receivables | 7683000 | 122000 | 6197.54 |
| accounts payables | 4339000 | 1122000 | 286.72 |
| inventory | -4262000 | -5197000 | 17.99 |
| acquisitions net | 0 | 0 | NaN |
| investments in property plant and equipment | -3889000 | -3878000 | -0.28 |
| net cash used for investing activites | -3618000 | 11947000 | -130.28 |
| debt repayment | 0 | 0 | NaN |
| common stock issued | -6241000 | 4603000 | -235.59 |
| common stock repurchased | 0 | 0 | NaN |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | 156000 | 4603000 | -96.61 |
| net change in cash | 18335000 | 24043000 | -23.74 |
| cash at end of period | 398159000 | 379824000 | 4.83 |
| cash at beginning of period | 379824000 | 355781000 | 6.76 |
Net Change in Cash: Net Change in Cash decreased to 18 million in 2024Q3 from 24 million in 2024Q2 representing a change of -23.74%. Indicating a declined ability to generate cash from the company's operations or its cash flow position.
Accounts Payables: The absolute value of Accounts Payables increased to 4 million in 2024Q3 from 1 million in 2024Q2 representing a change of 286.72%. This indicates that the company has increased its outstanding obligations to its suppliers.
Accounts Receivables: Accounts Receivables increased to 8 in 2024Q3 from 0 million in 2024Q2 representing a change of 6197.54%. This suggests that the company is less capable of collecting payments from its customers.
Operating Cash Flow: Operating Cash Flow increased to 22 million in 2024Q3 from 7 million in 2024Q2 representing a change of 188.7%. This indicates that the company generated more cash from its core business operations.
Free Cash Flow: Free Cash Flow increased to 18 million in 2024Q3 from 4 million in 2024Q2 representing a change of 390.66%. This indicates an increase in cash generated after accounting for capital expenditures.
Capital Expenditure: Capital Expenditure decreased to -4 million in 2024Q3 from -4 million in 2024Q2 representing a change of -0.28%. This indicates a possible improved efficiency or a shift in the company's strategic priorities.
Stock-Based Compensation: Stock-Based Compensation decreased to 34 million in 2024Q3 from 38 million in 2024Q2 representing a change of -12.74%. This indicates decreased expenses, which is generally considered a positive sign from a financial perspective.
We save you time by utilizing Generative AI to summarize earnings transcripts. Our summaries provide a clear insight into the company's current performance, future outlook, and overall sentiment expressed during the call. Click on below links to explore more.
Note: The years mentioned below are fiscal years in accounting.
Q3 2024 Earnings call transcript
EPS represents the portion of a company's profit allocated to each outstanding share of common stock. A higher EPS is generally favorable, indicating stronger profitability on a per-share basis.
Positive EPS: A positive EPS signifies that a company is profitable, it is generally viewed positively, supporting stock value and investor confidence.
Negative EPS: Indicates that a company is operating at a loss, which could lead to negative sentiment, potential stock depreciation, and concerns about the company's financial health.
The Next Earning Date represents when the company plans to release its next set of financial results.
An upward trend in EPS suggests consistent growth in earnings, often leading to increased investor confidence. A downward trend may indicate a decline in earnings, potentially decreasing investor confidence and stock value. Fluctuating EPS suggests unpredictable financial performance, warranting cautious investor analysis.
Earnings surprise occurs when a company's actual earnings differ from analysts' expectations. A positive earnings surprise typically reflects better-than-expected performance, potentially leading to stock appreciation. Conversely, a negative earnings surprise can result in stock depreciation. An earnings surprise of zero means the earnings met expectations, which typically has a neutral impact on stock price.
Discover detailed analyst recommendations for stocks, including categories such as Buy, Hold, Sell, Strong Buy, and Strong Sell. These insights are based on thorough analysis of financial and market factors. The consensus is calculated by assigning a numerical score to each recommendation. These scores are then weighted and averaged over a specified period to provide a comprehensive view of the stock's outlook, with the final score determining the overall consensus.
| 2023-12-31 | 2022-12-31 | Y/Y change % | |
|---|---|---|---|
| FY | |||
| calendar year | 2023 | 2022 | NaN |
| revenue per share | 5.28 | 4.54 | 16.43 |
| net income per share | -2.18 | -1.46 | -49.34 |
| operating cash flow per share | -0.13 | -0.3 | 56.06 |
| free cash flow per share | -0.55 | -1.45 | 61.94 |
| cash per share | 3.32 | 3.78 | -12.15 |
| book value per share | 6.32 | 7.08 | -10.63 |
| tangible book value per share | 6.14 | 6.84 | -10.12 |
| shareholders equity per share | 6.32 | 7.08 | -10.63 |
| interest debt per share | 0.81 | 0.84 | -3.07 |
| market cap | 6556555414.56 | 4149010444.96 | 58.03 |
| enterprise value | 6292641414.56 | 4024440444.96 | 56.36 |
| pe ratio | -25.7 | -24.99 | -2.83 |
| price to sales ratio | 10.6 | 8.03 | 31.89 |
| pocfratio | -431.44 | -123.46 | -249.45 |
| pfcf ratio | -101.3 | -25.1 | -303.53 |
| pb ratio | 8.85 | 5.15 | 71.82 |
| ptb ratio | 8.85 | 5.15 | 71.82 |
| ev to sales | 10.17 | 7.79 | 30.50 |
| enterprise value over ebitda | -30.68 | -31.32 | 2.05 |
| ev to operating cash flow | -414.07 | -119.75 | -245.77 |
| ev to free cash flow | -97.23 | -24.35 | -299.27 |
| earnings yield | -0.04 | -0.04 | 2.75 |
| free cash flow yield | -0.01 | -0.04 | 75.22 |
| debt to equity | 0.13 | 0.12 | 8.95 |
| debt to assets | 0.1 | 0.09 | 6.83 |
| net debt to ebitda | 1.29 | 0.97 | 32.72 |
| current ratio | 4.69 | 4.85 | -3.34 |
| interest coverage | -5907.55 | -352.82 | -1574.36 |
| income quality | 0.06 | 0.2 | -70.57 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 0.55 | 0.57 | -3.67 |
| research and ddevelopement to revenue | 0.44 | 0.51 | -15.07 |
| intangibles to total assets | 0.02 | 0.03 | -17.70 |
| capex to operating cash flow | -3.26 | -3.92 | 16.82 |
| capex to revenue | 0.08 | 0.25 | -68.61 |
| capex to depreciation | 1.14 | 3.99 | -71.54 |
| stock based compensation to revenue | 0.27 | 0.26 | 1.82 |
| graham number | 17.6 | 15.24 | 15.53 |
| roic | -0.24 | -0.19 | -25.25 |
| return on tangible assets | -0.27 | -0.17 | -63.05 |
| graham net net | 2.45 | 2.86 | -14.20 |
| working capital | 468860000 | 504078000 | -6.99 |
| tangible asset value | 719916000 | 778374000 | -7.51 |
| net current asset value | 371922000 | 411798000 | -9.68 |
| invested capital | 834919000 | 890657000 | -6.26 |
| average receivables | 109521500 | 94732500 | 15.61 |
| average payables | 18668500 | 19475000 | -4.14 |
| average inventory | 77667500 | 70797500 | 9.70 |
| days sales outstanding | 67.74 | 73.66 | -8.03 |
| days payables outstanding | 27.43 | 65.49 | -58.11 |
| days of inventory on hand | 128.47 | 247.49 | -48.09 |
| receivables turnover | 5.39 | 4.96 | 8.73 |
| payables turnover | 13.31 | 5.57 | 138.73 |
| inventory turnover | 2.84 | 1.47 | 92.65 |
| roe | -0.34 | -0.21 | -67.09 |
| capex per share | 0.42 | 1.16 | -63.45 |
ROE: Return on Equity (ROE) decreased to -0.34 on 2023-12-31 from -0.21 on 2022-12-31, representing a change of -67.09%. Suggesting that the company has not been generating high returns for its shareholders.
PE Ratio: Price-to-Earnings (P/E) Ratio decreased to -25.70 on 2023-12-31 from -24.99 on 2022-12-31, representing a change of -2.83%. Indicating a decrease in the relative valuation of the company's stock.
Current Ratio: Current Ratio decreased to 4.69 on 2023-12-31 from 4.85 on 2022-12-31, representing a change of -3.34%. The current ratio has been declining, suggesting a decrease in the company's short-term liquidity. Since it's above 3, indicating poor management of working capital.
Debt-to-Equity Ratio: Debt-to-Equity Ratio increased to 0.13 on 2023-12-31 from 0.12 on 2022-12-31, representing a change of 8.95%. The debt-to-equity ratio has been increasing, indicating that the company has been relying more on debt financing. Higher leverage may increase financial risk. However, a ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
| 2024-09-30 Q3 | 2024-06-30 Q2 | Q/Q change % | |
|---|---|---|---|
| TXG | |||
| calendar year | 2024 | 2024 | NaN |
| revenue per share | 1.26 | 1.28 | -1.49 |
| net income per share | -0.3 | -0.32 | 6.18 |
| operating cash flow per share | 0.18 | 0.06 | 187.11 |
| free cash flow per share | 0.15 | 0.03 | 387.95 |
| cash per share | 3.3 | 3.17 | 4.18 |
| book value per share | 5.99 | 6.03 | -0.72 |
| tangible book value per share | 5.82 | 5.85 | -0.66 |
| shareholders equity per share | 5.99 | 6.03 | -0.72 |
| interest debt per share | 0.71 | 0.75 | -4.56 |
| market cap | 2726151817.4 | 2232045009.48 | 22.14 |
| enterprise value | 2413868817.4 | 1941703009.48 | 24.32 |
| pe ratio | -19.06 | -14.72 | -29.46 |
| price to sales ratio | 17.98 | 14.58 | 23.30 |
| pocfratio | 125.97 | 297.76 | -57.69 |
| pfcf ratio | 153.57 | 616.93 | -75.11 |
| pb ratio | 3.77 | 3.08 | 22.35 |
| ptb ratio | 3.77 | 3.08 | 22.35 |
| ev to sales | 15.92 | 12.68 | 25.51 |
| enterprise value over ebitda | -101.91 | -74.17 | -37.40 |
| ev to operating cash flow | 111.54 | 259.03 | -56.94 |
| ev to free cash flow | 135.98 | 536.68 | -74.66 |
| earnings yield | -0.01 | -0.02 | 22.76 |
| free cash flow yield | 0.01 | 0.0 | 301.73 |
| debt to equity | 0.12 | 0.12 | -3.86 |
| debt to assets | 0.09 | 0.1 | -4.86 |
| net debt to ebitda | 13.18 | 11.09 | 18.87 |
| current ratio | 4.9 | 5.22 | -6.10 |
| interest coverage | -20742.5 | -41737 | 50.30 |
| income quality | -0.61 | -0.2 | -206.01 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 0 | 0 | NaN |
| research and ddevelopement to revenue | 0.44 | 0.41 | 6.18 |
| intangibles to total assets | 0.02 | 0.02 | -3.25 |
| capex to operating cash flow | 0.18 | 0.52 | -65.26 |
| capex to revenue | 0.03 | 0.03 | 1.24 |
| capex to depreciation | 0.36 | 0.36 | 1.68 |
| stock based compensation to revenue | 0.22 | 0.25 | -11.91 |
| graham number | 6.32 | 6.54 | -3.49 |
| roic | -0.05 | -0.05 | -1.56 |
| return on tangible assets | -0.04 | -0.04 | 6.55 |
| graham net net | 2.43 | 2.39 | 1.47 |
| working capital | 472658000 | 468136000 | 0.97 |
| tangible asset value | 702144000 | 702889000 | -0.11 |
| net current asset value | 378903000 | 373545000 | 1.43 |
| invested capital | 811656000 | 813462000 | -0.22 |
| average receivables | 87351500 | 91241500 | -4.26 |
| average payables | 23729000 | 20732000 | 14.46 |
| average inventory | 91161000 | 85730500 | 6.33 |
| days sales outstanding | 49.57 | 53.6 | -7.52 |
| days payables outstanding | 52.12 | 41.39 | 25.93 |
| days of inventory on hand | 187.02 | 171.93 | 8.77 |
| receivables turnover | 1.82 | 1.68 | 8.13 |
| payables turnover | 1.73 | 2.17 | -20.59 |
| inventory turnover | 0.48 | 0.52 | -8.07 |
| roe | -0.05 | -0.05 | 5.49 |
| capex per share | 0.03 | 0.03 | -0.27 |
ROE: Return on Equity (ROE) decreased to -0.05 on 2024-09-30 Q3 from -0.05 on 2024-06-30 Q2, representing a change of 5.49%. Suggesting that the company has not been generating high returns for its shareholders.
PE Ratio: Price-to-Earnings (P/E) Ratio decreased to -19.06 on 2024-09-30 Q3 from -14.72 on 2024-06-30 Q2, representing a change of -29.46%. Indicating a decrease in the relative valuation of the company's stock.
Current Ratio: Current Ratio decreased to 4.90 on 2024-09-30 Q3 from 5.22 on 2024-06-30 Q2, representing a change of -6.10%. The current ratio has been declining, suggesting a decrease in the company's short-term liquidity. Since it's above 3, indicating poor management of working capital.
Debt-to-Equity Ratio: Debt-to-Equity Ratio decreased to 0.12 on 2024-09-30 Q3 from 0.12 on 2024-06-30 Q2, representing a change of -3.86%. The debt-to-equity ratio has been decreasing, indicating that the company has been relying less on debt financing. A ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
None
| Market Capitalization | Enterprise Value | |
|---|---|---|
| Definition | The total market value of a company's outstanding shares | The total market value of a company, including its debt and other liabilities |
| Calculation | Current share price * Total number of outstanding shares | Market capitalization + Total debt - Cash and cash equivalents |
| Focus | Equity component of a company's value | Total economic value of a company |
| Usefulness | Assesses a company's size and growth potential based on investor sentiment | Provides a more comprehensive valuation that considers both equity and debt |
Analyzing dividends is a crucial aspect of investment evaluation, offering valuable insights into a company's financial health and its commitment to shareholder returns. Dividends represent a portion of a company's profits distributed to its shareholders, providing a steady income stream. We help you analyze dividends based on the indicators mentioned below:
• Investors often assess the average dividend amount, observing trends over time to gauge the company's stability and growth potential. A positive trend in average dividends indicates a consistent and potentially lucrative investment. Additionally, evaluating the trend of dividend increases provides insight into the company's financial strength and management's confidence in future earnings.
• Consistency in paying dividends is a reassuring sign, reflecting a company's reliability and commitment to shareholder value. For investors, dividends not only offer income but also contribute to the overall total return on investment.
• Companies with a history of regular and increasing dividends can attract income-focused investors seeking stable returns, making dividends a critical factor in building a well-rounded investment portfolio.
Interested in the overall sentiment for a particular period? Check out our news sentiment analysis tool.
Sentiment: Positive
Publish Date: 2025-01-14 18:00:00
On track to return to positive free cash flow mid-year as Media Luna ramps up (All amounts expressed in U.S. dollars unless otherwise stated) Toronto, Ontario--(Newsfile Corp. - January 14, 2025) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) provides 2025 operational guidance as well as an updated five-year production outlook for the Morelos Complex. Full-year guidance assumes a four-week shutdown of the processing plant during the first quarter to carry out upgrades and tie-ins required to complete the Media Luna Project.
Sentiment: Positive
Publish Date: 2025-01-08 18:00:00
2024 marks the sixth consecutive year production guidance has been achieved Toronto, Ontario--(Newsfile Corp. - January 8, 2025) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) reports fourth quarter gold production of 103,795 ounces ("oz") and full-year gold production of 452,523 oz, within the Company's revised guidance range of 450,000 to 470,000 oz (original guidance of 400,000 to 450,000 oz). Fourth quarter and full-year gold sold were 108,647 oz and 455,932 oz, respectively.
Sentiment: Neutral
Publish Date: 2025-01-02 16:05:00
PLEASANTON, Calif. , Jan. 2, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that members of its management team will present at the 43rd Annual J.P.
Sentiment: Positive
Publish Date: 2024-12-24 07:30:00
Even the perpetually moving Cathie Wood takes a step back over the holidays. The co-founder, CEO, and investment manager for Ark Invest has been slowing the pace of her portfolio moves lately.
Sentiment: Positive
Publish Date: 2024-12-23 16:05:00
PLEASANTON, Calif. , Dec. 23, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today it had secured a permanent injunction in the U.S. District Court for the District of Delaware against the GeoMx products sold by Bruker Corporation (Nasdaq: BRKR), which acquired the product line from NanoString Technologies.
Sentiment: Neutral
Publish Date: 2024-12-17 16:57:00
Toronto, Ontario--(Newsfile Corp. - December 17, 2024) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) reports that the Director General of Mines under the Federal Ministry of Economy has lifted the temporary suspension notice and allowed for all activities within the Morelos Complex to resume. Jody Kuzenko, President & CEO of Torex, stated: "Following notification that the temporary suspension has been lifted by the Director General of Mines, all production and development activities at the Morelos Complex will resume, including open pit and underground mining, processing operations, and all activities associated with the Media Luna Project.
Sentiment: Negative
Publish Date: 2024-12-09 20:00:00
Toronto, Ontario--(Newsfile Corp. - December 9, 2024) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) reports that the Company has received a notification from the Director General of Mines under the Federal Ministry of Economy that all activities within the Morelos Property are to be temporarily suspended to support their inspection associated with the fatal incident at the El Limón Guajes underground mine ("ELG Underground") on December 5th. As a result, all operational and project activities within the Morelos Complex have been temporarily halted pending permission from officials to resume activities.
Sentiment: Negative
Publish Date: 2024-12-09 06:00:00
Toronto, Ontario--(Newsfile Corp. - December 9, 2024) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) provides an update on the carbon monoxide exposure at the El Limón Guajes underground mine ("ELG Underground") that claimed the lives of two employees and one contractor and injured a second contractor. The relevant authorities have all been notified and the Company is fully cooperating with regulators.
Sentiment: Negative
Publish Date: 2024-12-05 18:30:00
Toronto, Ontario--(Newsfile Corp. - December 5, 2024) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) regretfully announces that during the day shift on December 5th, a fatal carbon monoxide gas exposure occurred, which claimed the lives of two employees and one contractor at the El Limón Guajes underground mine ("ELG Underground"). A fourth contract employee was also in the area and is currently in hospital and expected to recover.
Sentiment: Positive
Publish Date: 2024-12-02 18:00:00
Results continue to indicate impressive grades and ongoing potential to expand resources and replace mined reserves (All amounts expressed in U.S. dollars unless otherwise stated) Toronto, Ontario--(Newsfile Corp. - December 2, 2024) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) announces further assay results from the Company's 2024 drilling program at ELG Underground. The results to date support the Company's target of extending the mine life of ELG Underground by identifying new zones of higher-grade mineralization, expanding resources, and replacing and growing reserves.
Sentiment: Positive
Publish Date: 2024-11-19 06:00:00
Toronto, Ontario--(Newsfile Corp. - November 19, 2024) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) announces that it has received approval from the Toronto Stock Exchange (the "TSX") of its notice of intention to make a normal course issuer bid (the "NCIB"). Under the NCIB, Torex is authorized to purchase up to 7,116,777 of its common shares ("Common Shares"), representing approximately 10% of the public float as of November 13, 2024, during the period commencing on November 21, 2024 and ending on November 20, 2025.
Sentiment: Positive
Publish Date: 2024-11-13 18:00:00
Results indicate strong potential to upgrade Inferred Resources to Indicated Resources and expand resources to the north of the deposit (All amounts expressed in U.S. dollars unless otherwise stated) Toronto, Ontario--(Newsfile Corp. - November 13, 2024) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) announces assay results from the Company's ongoing drilling program at EPO. The results to date support Torex's goal of expanding resources to the north of the deposit and upgrading Inferred Resources to Indicated Resources.
Sentiment: Neutral
Publish Date: 2024-11-07 16:05:00
PLEASANTON, Calif. , Nov. 7, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that members of its management team will participate in a fireside chat at the Wolfe Research 2024 Healthcare Conference on Tuesday, November 19, at 1:00 p.m.
Sentiment: Positive
Publish Date: 2024-11-06 18:00:00
Solid financial performance and robust cash generation driven by an all-in sustaining costs margin of 52% (All amounts expressed in U.S. dollars unless otherwise stated) Toronto, Ontario--(Newsfile Corp. - November 6, 2024) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) reports the Company's financial and operational results for the three and nine months ended September 30, 2024. Torex will host a conference call tomorrow morning at 9:00 AM (ET) to discuss the results.
Sentiment: Negative
Publish Date: 2024-10-31 08:00:00
Cure51 plans to analyze more than 1,000 tumor samples from exceptional cancer survivors PARIS and PLEASANTON, Calif. , Oct. 31, 2024 /PRNewswire/ -- French TechBio startup Cure51 and 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that Cure51 will deploy 10x Genomics' Visium HD as part of its pioneering work to understand the unique biology of exceptional cancer survivors, whose survival mechanisms could hold the key to new therapeutic approaches.
Sentiment: Positive
Publish Date: 2024-10-30 18:00:00
Project 87% complete; plant tie-in schedule moves to February; first copper concentrate expected in Q1 (All amounts expressed in U.S. dollars unless otherwise stated) Toronto, Ontario--(Newsfile Corp. - October 30, 2024) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) provides a Q3 2024 update on the development of its Media Luna Project ("Media Luna") and increases 2024 production guidance with a decision to undertake the tie-ins and upgrades to the processing plant in February 2025. Unless otherwise stated, progress and milestones referenced in this press release are as of September 30, 2024.
Sentiment: Positive
Publish Date: 2024-10-30 14:41:30
10x Genomics, Inc. TXG reported a loss for the third quarter on Tuesday.
Sentiment: Positive
Publish Date: 2024-10-29 20:04:08
10x Genomics, Inc. (NASDAQ:TXG ) Q3 2024 Earnings Conference Call October 29, 2024 4:30 PM ET Company Participants Cassie Corneau - Senior Director, Head of Investor Relations and Strategic Finance Serge Saxonov - Chief Executive Officer and Co-Founder Adam Taich - Chief Financial Officer Conference Call Participants Tejas Savant - Morgan Stanley Tycho Peterson - Jefferies Doug Schenkel - Wolfe Research Dan Arias - Stifel Nicolaus Dan Brennan - TD Cowen Mason Carrico - Stephens Puneet Souda - Leerink Partners Rachel Vatnsdal - J.P. Morgan Kyle Mikson - Canaccord Genuity Patrick Donnelly - Citi Michael Ryskin - Bank of America Subbu Nambi - Guggenheim Securities Matt Larew - William Blair Matt Sykes - Goldman Sachs Operator Thank you for standing by.
Sentiment: Positive
Publish Date: 2024-10-29 20:01:12
The headline numbers for 10x Genomics (TXG) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Sentiment: Negative
Publish Date: 2024-10-29 18:20:22
10x Genomics (TXG) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.51 per share a year ago.
* The sentiment analysis presented is generated through an algorithm and may be subject to inaccuracies. Users are advised to corroborate key information and employ further analytical methods prior to making critical decisions.
Get instant AI-powered professional insights:
💡Generate AI Technical Analysis ReportUnderstand the chart below:
Interpret Technical Indicators
| Indicator | Bullish | Bearish |
|---|---|---|
| Price and EMA ⓘ | Price crosses above EMA | Price crosses below EMA |
| Short-Term vs Long-Term EMA ⓘ | Short EMA crosses above Long EMA | Short EMA crosses below Long EMA |
| Volume ⓘ | Increasing volume during price uptrend | Increasing volume during price downtrend |
| MACD ⓘ | MACD crosses above Signal Line | MACD crosses below Signal Line |
| RSI ⓘ | RSI is below 30 (oversold) and starts to rise above 30 | RSI is above 70 (overbought) and starts to decline below 70 |
| Candlestick Patterns ⓘ | Bullish candlestick patterns | Bearish candlestick patterns |
Copyright © 2024 Sirius Investors
All rights reserved
